Literature DB >> 19033423

Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2.

Fusun Baumann1, Petra Leukel, Anett Doerfelt, Christoph P Beier, Katja Dettmer, Peter J Oefner, Michael Kastenberger, Marina Kreutz, Thomas Nickl-Jockschat, Ulrich Bogdahn, Anja-Katrin Bosserhoff, Peter Hau.   

Abstract

Lactate dehydrogenase type A (LDH-A) is a key metabolic enzyme catalyzing pyruvate into lactate and is excessively expressed by tumor cells. Transforming growth factor-beta2 (TGF-beta2) is a key regulator of invasion in high-grade gliomas, partially by inducing a mesenchymal phenotype and by remodeling the extracellular matrix. In this study, we tested the hypothesis that lactate metabolism regulates TGF-beta2-mediated migration of glioma cells. Small interfering RNA directed against LDH-A (siLDH-A) suppresses, and lactate induces, TGF-beta2 expression, suggesting that lactate metabolism is strongly associated with TGF-beta2 in glioma cells. Here we demonstrate that TGF-beta2 enhances expression, secretion, and activation of matrix metalloproteinase-2 (MMP-2) and induces the cell surface expression of integrin alpha(v)beta(3) receptors. In spheroid and Boyden chamber migration assays, inhibition of MMP-2 activity using a specific MMP-2 inhibitor and blocking of integrin alpha(v)beta(3) abrogated glioma cell migration stimulated by TGF-beta2. Furthermore, siLDH-A inhibited MMP2 activity, leading to inhibition of glioma migration. Taken together, we define an LDH-A-induced and TGF-beta2-coordinated regulatory cascade of transcriptional regulation of MMP-2 and integrin alpha(v)beta(3). This novel interaction between lactate metabolism and TGF-beta2 might constitute a crucial mechanism for glioma migration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19033423      PMCID: PMC2743217          DOI: 10.1215/15228517-2008-106

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  44 in total

1.  Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas.

Authors:  J D Stiles; P T Ostrow; L L Balos; S J Greenberg; R Plunkett; W Grand; R R Heffner
Journal:  J Neuropathol Exp Neurol       Date:  1997-04       Impact factor: 3.685

2.  An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis.

Authors:  A C Williams; T J Collard; C Paraskeva
Journal:  Oncogene       Date:  1999-05-27       Impact factor: 9.867

3.  Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2.

Authors:  E I Deryugina; G X Luo; R A Reisfeld; M A Bourdon; A Strongin
Journal:  Anticancer Res       Date:  1997 Sep-Oct       Impact factor: 2.480

4.  Comparative analysis of matrix metalloproteinases by immunocytochemistry, immunohistochemistry and zymography in human primary brain tumours.

Authors:  H K Rooprai; T Van Meter; G J Rucklidge; L Hudson; I P Everall; G J Pilkington
Journal:  Int J Oncol       Date:  1998-12       Impact factor: 5.650

5.  Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo.

Authors:  R E Sawaya; M Yamamoto; Z L Gokaslan; S W Wang; S Mohanam; G N Fuller; I E McCutcheon; W G Stetler-Stevenson; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1996-01       Impact factor: 5.150

6.  Identification of a silencer module which selectively represses cyclic AMP-responsive element-dependent gene expression.

Authors:  K C Chung; D Huang; Y Chen; S Short; M L Short; Z Zhang; R A Jungmann
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

7.  Matrix metalloproteinase-2 activation modulates glioma cell migration.

Authors:  E I Deryugina; M A Bourdon; G X Luo; R A Reisfeld; A Strongin
Journal:  J Cell Sci       Date:  1997-10       Impact factor: 5.285

8.  Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.

Authors:  P A Forsyth; H Wong; T D Laing; N B Rewcastle; D G Morris; H Muzik; K J Leco; R N Johnston; P M Brasher; G Sutherland; D R Edwards
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  Acidic environment causes apoptosis by increasing caspase activity.

Authors:  H J Park; J C Lyons; T Ohtsubo; C W Song
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

10.  Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors.

Authors:  C L Gladson; J N Wilcox; L Sanders; G Y Gillespie; D A Cheresh
Journal:  J Cell Sci       Date:  1995-03       Impact factor: 5.285

View more
  81 in total

Review 1.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Authors:  Michelle M Kim; Abhijit Parolia; Mark P Dunphy; Sriram Venneti
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

2.  Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study.

Authors:  Chaim B Colen; Yimin Shen; Farhad Ghoddoussi; Pingyang Yu; Todd B Francis; Brandon J Koch; Michael D Monterey; Matthew P Galloway; Andrew E Sloan; Saroj P Mathupala
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

Review 3.  Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Authors:  Nissim Hay
Journal:  Nat Rev Cancer       Date:  2016-09-16       Impact factor: 60.716

4.  A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.

Authors:  Alba A Brandes; Antoine F Carpentier; Santosh Kesari; Juan M Sepulveda-Sanchez; Helen R Wheeler; Olivier Chinot; Lawrence Cher; Joachim P Steinbach; David Capper; Pol Specenier; Jordi Rodon; Ann Cleverly; Claire Smith; Ivelina Gueorguieva; Colin Miles; Susan C Guba; Durisala Desaiah; Michael M Lahn; Wolfgang Wick
Journal:  Neuro Oncol       Date:  2016-02-21       Impact factor: 12.300

5.  Targeted sensitization of tumor cells for radiation through monocarboxylate transporters 1 and 4 inhibition in vitro.

Authors:  Gregor Brandstetter; Sebastian Blatt; Jutta Goldschmitt; Louise Taylor; Paul Heymann; Bilal Al-Nawas; Thomas Ziebart
Journal:  Clin Oral Investig       Date:  2020-06-03       Impact factor: 3.573

Review 6.  Tumors as organs: biologically augmenting radiation therapy by inhibiting transforming growth factor β activity in carcinomas.

Authors:  Shisuo Du; Mary Helen Barcellos-Hoff
Journal:  Semin Radiat Oncol       Date:  2013-10       Impact factor: 5.934

7.  Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis.

Authors:  L Jin; J Chun; C Pan; G N Alesi; D Li; K R Magliocca; Y Kang; Z G Chen; D M Shin; F R Khuri; J Fan; S Kang
Journal:  Oncogene       Date:  2017-02-20       Impact factor: 9.867

8.  Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets.

Authors:  Vera Miranda-Gonçalves; Mrinalini Honavar; Céline Pinheiro; Olga Martinho; Manuel M Pires; Célia Pinheiro; Michelle Cordeiro; Gil Bebiano; Paulo Costa; Isabel Palmeirim; Rui M Reis; Fátima Baltazar
Journal:  Neuro Oncol       Date:  2012-12-20       Impact factor: 12.300

Review 9.  Lactate modulation of immune responses in inflammatory versus tumour microenvironments.

Authors:  Michelangelo Certo; Chin-Hsien Tsai; Valentina Pucino; Ping-Chih Ho; Claudio Mauro
Journal:  Nat Rev Immunol       Date:  2020-08-24       Impact factor: 53.106

10.  Bex2 is critical for migration and invasion in malignant glioma cells.

Authors:  Xiuping Zhou; Xuebin Xu; Qingming Meng; Jinxia Hu; Tongle Zhi; Qiong Shi; Rutong Yu
Journal:  J Mol Neurosci       Date:  2012-08-03       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.